Michel Vounatsos
Director/Board Member at REVVITY, INC.
Net worth: 15 M $ as of 2024-03-30
Profile
Michel Vounatsos is on the board of PerkinElmer, Inc. (United States), L’Institut de RYthmologie et Modélisation Cardiaque and n-Lorem Foundation and Chief Executive Officer & Director at Biogen, Inc. In his past career he occupied the position of President-Primary Care & Customer Business Line at Merck & Co., Inc. Mr. Vounatsos received an MBA from École des Hautes Études Commerciales de Paris.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOGEN INC.
0.05% | 2023-04-27 | 67,262 ( 0.05% ) | 15 M $ | 2024-03-30 |
REVVITY, INC.
0.01% | 2023-05-14 | 6,486 ( 0.01% ) | 681 030 $ | 2024-03-30 |
ZAI LAB LTD.
0.02% | 2023-06-29 | 183,320 ( 0.02% ) | 302 159 $ | 2024-03-30 |
Michel Vounatsos active positions
| Companies | Position | Start |
|---|---|---|
| REVVITY, INC. | Director/Board Member | 2020-02-29 |
| ZAI LAB LIMITED | Director/Board Member | 2023-01-06 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Chief Executive Officer | 2017-01-05 |
Biogen GmbH
 Biogen GmbH Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The private company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos. | Chief Executive Officer | - |
| L’Institut de RYthmologie et Modélisation Cardiaque | Chairman | - |
| n-Lorem Foundation | Director/Board Member | - |
Revvity BV
 Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | Director/Board Member | - |
Former positions of Michel Vounatsos
| Companies | Position | End |
|---|---|---|
| BIOGEN INC. | Chief Executive Officer | 2022-11-13 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2016-03-31 |
Training of Michel Vounatsos
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| REVVITY, INC. | Health Technology |
| ZAI LAB LIMITED | Health Technology |
| Private companies | 5 |
|---|---|
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | Health Technology |
| L’Institut de RYthmologie et Modélisation Cardiaque | |
| n-Lorem Foundation | |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen GmbH is a pioneer in the field of neuroscience since 1978. The private company is based in Ismaning, Germany. Biogen focuses on research in therapeutic areas with a strong emphasis on difficult-to-treat diseases. The German company was founded in 1978 by Charles Weissman, Kenneth Murray, Heinz Schaller, Phillip Sharp, Walter Gilbert. The CEO is Michel Pericles Vounatsos. | Health Technology |
- Stock Market
- Insiders
- Michel Vounatsos
